Podcasts about Gleason

Send a textWhat if one of the biggest sources of diagnostic variability in prostate cancer isn't the pathologist—but the stain we've trusted for decades?In this episode, I speak with Professor Ingied Carlbom, founder of CADESS.AI, about a different way to approach prostate cancer grading—by rethinking staining, segmentation, and AI decision support from the ground up. We explore why 30–40% interobserver variability persists in Gleason grading and how optimized stains combined with explainable AI can significantly reduce that uncertainty.Ingred shares her journey from applied mathematics and computer science into pathology, the skepticism she faced in 2008, and why CADESS.AI chose not to “optimize H&E,” but instead developed a Picrosirius red + hematoxylin stain designed specifically for computational pathology. We discuss how grading at the gland and cellular level improves reproducibility, why explainability matters for trust, and what it really takes to build both stain and software as a single diagnostic workflow.This conversation challenges long-held assumptions—and asks whether improving data quality should come before building smarter algorithms.Highlights:[00:00–01:08] The problem: 30–40% disagreement in prostate cancer grading[01:08–03:03] Ingrid's path from applied math to digital pathology[03:03–04:58] Early skepticism toward AI in pathology and fear of replacement[04:58–08:56] Why H&E limits segmentation—and how a new stain changes that[10:55–15:09] Clinical testing: non-inferiority, AI assistance, and NCCN risk stratification[19:47–22:59] Explainable UI: color-coded glands and pathologist override[26:16–27:29] Why grading glands (not whole slides) reduces variability[38:09–41:47] Regulatory challenges of combined stain + AI devices[45:52–48:55] The future of optimized stains in routine pathologyResources from This EpisodeCADESS.AI – Prostate cancer decision support systemNCCN prostate cancer risk stratification guidelinesSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Readings: Genesis 2:15-17; 3:1-7 | Romans 5:12-19 | Matthew 4:1-11 | Psalm 32. Preached for the First Sunday in Lent (2026-02-22).

Send a textIs AI in pathology actually improving diagnosis — or just adding complexity?In DigiPath Digest #37, we reviewed four recent publications covering AI-based biomarker quantification in glioblastoma, real-world digital workflow integration in prostate cancer, multimodal AI combining histopathology and genomics, and patient perspectives on AI in cancer diagnostics.This episode connects technical performance with something equally important: trust.Episode Highlights[00:02] Community & updates Digital Pathology 101 free PDF, upcoming patient-focused book, and global attendance.[04:07] AI-based image analysis in glioblastoma AI showed strong consistency with pathologists when quantifying Ki-67, P53, and PHH3. Significant biological correlations (Ki-67 ↔ PHH3, PHH3 ↔ P53) were detected by AI — not by manual assessment. Takeaway: computational quantification improves precision.[09:28] Real-world digital workflow + AI in prostate cancer (France) AI-pathologist concordance: • 93.2% (high probability cancer detection) • 99.0% (low probability slides) Gleason concordance: 76.6% 10% failure rate due to pre-analytical artifacts. Takeaway: infrastructure and sample quality still matter.[15:58] Multimodal AI (MARBIX framework) Combines whole slide images + immunogenomic data in a shared latent space using binary “monograms.” Performance in lung cancer: 85–89% vs 69–76% unimodal models. Takeaway: integrated data improves case retrieval and similarity reasoning.[22:13] AI-powered paper summary subscription introduced Structured summaries for busy professionals who want more than abstracts.[26:17] Patient roundtable on AI in pathology (Belgium) Patients expect: • Better accuracy • Faster turnaround • Stronger collaborationTrust is high when: • Algorithms use diverse datasets • Pathologists retain final responsibilityClinical validity mattered more than full algorithm transparency. Privacy concerns focused more on insurer misuse than cloud transfer.Key TakeawaysAI improves biomarker precision in glioblastoma.Digital pathology implementation works — but pre-analytics can limit AI performance.Multimodal AI represents the next meaningful step in precision diagnostics.Patients are not afraid of AI — they want validation, oversight, and governance.Human–AI collaboration remains central.If you're working in digital pathology, computational pathology, or precision oncology, this episode connects evidence, implementation, and patient perspective.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

The daughter of a hospital administrator, Amy Gleason never considered a career in the public sector – she went straight into healthcare. As an emergency room nurse, she started to see the dangers that unfold when healthcare providers don't have access to the information they need to treat patients. Those experiences drove her towards a tech career in the emerging electronic health records space before a very personal experience altered her professional path yet again.Amy's active and healthy 10-year old daughter began suffering unusual healthcare events, from rashes and headaches to broken bones. Eventually, she couldn't walk. It took more than a year from the start of these symptoms for doctors to diagnose her with a rare autoimmune disease. Even then, it was an accidental diagnosis from a dermatologist conducting a skin biopsy.Amy attributes the delayed diagnosis to siloed data, not unsimilar to the challenges she experienced as a nurse and was working to solve in the EHR space. It motivated her to co-found a company focused on helping patients with chronic diseases access their data to share it with the providers and family members helping to navigate complex care journeys.In 2015, Amy's work earned her an award from the White House for Champions of Change in Precision Medicine – her first foray into the public sector. By 2018, she entered civic service full time with a role at the United States Digital Service, which she describes as “DOGE 1.0.”In this episode of Healthcare is Hard, Amy talked to Keith Figlioli about the work she's doing now as Strategic Advisor to CMS and Administrator of the U.S. DOGE Service, where her main mission is modernizing technology across government agencies for the millions of people who rely on federal services every day. This ranges from modernizing FAFSA and the student loan process, to improving the Visa system ahead of the World Cup, and work on various critical healthcare systems. Some of the topics Amy and Keith discussed in this episode, include:Bold plans for a Digital Health Ecosystem. Launched in July 2025, CMS' Health Tech Ecosystem is a public-private partnership designed as a voluntary, fast-moving alternative to slow rulemaking. Rather than years of regulation, the program uses pledges, working groups, and short development cycles to put interoperability building blocks and real patient-facing use cases in place. The goal is to get usable capabilities into the market in months – not years – let the community iterate, and have baseline use cases live by March 31, 2026 with more advanced capabilities rolling out by July.Carrots and sticks before regulation. Recognizing the limitations of regulation, Amy talked about a new philosophy for incentivizing the market to change behaviors on its own first. “Carrots” include the rural health transformation fund and the recently introduced ACCESS model, a 10-year pilot that, for the first time, lets tech-enabled services bill Medicare directly. “Sticks” include stricter enforcement of information-blocking rules.Replacing the 1970s-era Medicare claims system. Amy discussed plans to replace Medicare's decades-old COBOL-based adjudication platform. While it's a stable platform, it can't support real-time processing, AI, or rapid change. To replace it, CMS is looking to commercial, off-the-shelf solutions that operate at scale so claims processing can be modernized, made real-time, and integrated with new interoperability rails. It's a concrete example of bringing modern engineering and product thinking to government technology.To hear Amy and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

In this episode of The Dish on Health IT, host Tony Schueth is joined by co-host Alix Goss and special guest Amy Gleason, Strategic Advisor to Centers for Medicare & Medicaid Services (CMS) and Administrator of the U.S. Department of Government Efficiency (DOGE) Service, for a wide-ranging discussion on how health IT modernization is evolving under a pledge-driven, incentive-backed federal strategy.The conversation begins not with policy, but with lived experience.From Emergency Room to Interoperability AdvocateAmy shares how her early career as an emergency room nurse exposed the dangers of fragmented information. Providers were expected to make critical decisions without access to complete patient histories, while patients, often in pain or distress, were unrealistically asked to recall complex medical details.That professional frustration became deeply personal when her daughter went more than a year without diagnosis for a rare autoimmune disease, juvenile dermatomyositis (JDM). Multiple specialists saw pieces of the puzzle, but no one could see the full picture across charts and settings. Amy reflects that if today's AI tools had been applied to her daughter's complete longitudinal record, the condition may have surfaced sooner.That experience shaped her philosophy. Technology must converge with policy and trust in ways that tangibly improve care.Why Pledges Instead of Rules?Tony presses on a central theme. Amy has argued that we cannot regulate our way to success. Why pursue voluntary pledges instead of federal rulemaking?Amy explains her frustration returning to government in 2025 to find interoperability policies she helped draft in 2020 still not fully effective until 2027. Seven years is an eternity in technology. Meanwhile, the industry had technically complied with numerous mandates including Meaningful Use, Cures Act APIs and CMS interoperability rules, yet many workflows still felt broken.In her view, regulation created a floor but not always real transformation.The CMS Health Tech Ecosystem Pledge was launched as a different model. The federal government used its convening power to articulate a clear vision and challenge industry to deliver minimum viable products within six to twelve months rather than years.Initially announced with roughly 60 companies, the pledge initiative has grown to more than 600 participants collaborating in working groups. The three initial patient-focused use cases include:Improving data interoperability“Killing the clipboard” through digital identity and QR-based sharingLeveraging conversational AI and personalized recommendations for chronic conditions such as diabetes and obesityAmy describes live demonstrations at a Connectathon showing OAuth-enabled data retrieval, QR ingestion into EHR workflows and AI-powered recommendations built on patient data. The goal is not perfection by the first milestone, but real-world minimum viable functionality that can iteratively improve.Alix notes that from the standards community perspective, this approach feels aligned with long-standing calls for industry-driven collaboration, though it remains early to measure widespread impact.Carrots, Sticks and Rural HealthThe discussion turns to incentives.Amy outlines the administration's carrots and sticks strategy:Stick: Enforcement of information blocking, with penalties up to $2 million per occurrenceCarrots: Financial incentives such as the $50 billion Rural Health Transformation Program and the CMS ACCESS Model, which pays for technology-enabled outcomesThe Rural Health Transformation Program directs money to states with expectations that ecosystem-aligned interoperability and app participation be incorporated into funding proposals. CMS retains oversight and clawback authority to ensure funds support rural providers.The ACCESS Model represents a significant shift. Technology-enabled care platforms can register as Medicare Part B providers and be paid for measurable outcomes in tracks such as cardiometabolic disease, musculoskeletal conditions and behavioral health. Providers remain in the loop and receive compensation for referral and care plan oversight.Alix underscores that rural providers face steep financial and workforce constraints. Standards participation, implementation and technology upgrades require resources that are often scarce. The success of these incentives will depend on whether they reduce burden rather than add to it.AI: Evolution, Risk and RealityAI becomes a central thread of the episode.Amy compares AI adoption to autonomous vehicle models. Some scenarios allow tightly controlled automation, such as medication refills, while others require a human in the loop for higher-risk decisions. She points to a Utah prescription refill pilot as an example of bounded automation, where malpractice coverage and clearly defined use cases mitigate risk.When Tony asks who owns risk in this evolving landscape, Amy emphasizes the need for light but clear regulatory pathways rather than fragmented state-by-state oversight.Patients, she notes, are already there. Millions are asking health-related questions weekly through AI tools. The more pressing issue is ensuring those tools are grounded in structured medical data rather than incomplete memory or unverified inputs.She shares a striking story. Her daughter was excluded from a clinical trial due to a misclassification of ulcerative colitis. By uploading her records into an AI model, they identified a more precise diagnosis, microscopic lymphocytic colitis, which did not disqualify her from the trial. For Amy, this demonstrates both the power and inevitability of AI use.Alix adds caution. AI is only as strong as the data beneath it. Dirty, inconsistent and poorly structured data limits performance. Standards and terminologies remain essential to fuel high-fidelity models and safeguard trust.FHIR, Deregulation and the Data FoundationThe conversation addresses an emerging tension. If regulatory burdens are being reduced, does that signal less need for structured standards like FHIR?Amy candidly admits she initially wondered whether AI might reduce the need for FHIR altogether. After discussions with labs and technologists, she concluded the opposite. Standardized data dramatically improves AI performance and reduces error.Deregulation is about removing unnecessary burden, not abandoning foundational data structures.Alix reinforces that FHIR enables discrete, normalized data capture that supports both legacy transactions and AI evolution. While future innovations may emerge, today FHIR remains the backbone for scalable interoperability.Prior Authorization and HIPAA ModernizationThe episode dives into prior authorization modernization across medical and pharmacy domains.Amy notes growing interest among pledge participants to expand into pharmacy prior authorization testing, diagnostic imaging, real-time benefit checks and bulk FHIR performance testing.Alix provides insight into ongoing work within the Designated Standards Maintenance Organizations to incorporate FHIR-based approaches into HIPAA-named standards, particularly for prior authorization. She highlights testing beyond Connectathons, including implementer communities and real-world pilot efforts.Both stress the importance of public comment periods and industry engagement, describing participation as a civic responsibility for health IT professionals.Trust as the Core EnablerThe final segment centers on trust.Amy explains that the ecosystem initiative aims to reinforce trust through:Stronger digital identity verification such as Clear, ID.me and Login.govCertification frameworks such as CARIN and DIME for patient-facing appsA new national provider directory to replace fragmented provider data sourcesTransparency dashboards showing data requests, volumes and purposeRather than replacing frameworks like TEFCA, she describes the pledge model as an accelerator layered above the regulatory floor.Transparency acts as sunlight, enabling visibility into who is accessing data and for what purpose.Final TakeawaysIn closing, Amy urges providers not to sit on the sidelines. Too often, she says, providers feel change is imposed on them. The pledge environment is designed as an open forum where they can directly shape what works or does not work in real workflows.Alix echoes the call. Standards require participation. Organizations must allocate budget and staff to engage, comment and collaborate. It truly takes a village.Tony concludes by framing the episode's core message. Regulation establishes baseline expectations, but voluntary movements can demonstrate what is possible before mandates reach the Federal Register.Across pledges, payment reform, AI evolution and trust frameworks, the episode underscores a consistent theme. Modernization in health IT depends not only on policy direction, but on shared accountability and active participation from every stakeholder in the ecosystem.Listeners are reminded that POCP is available to support organizations in understanding the implications of federal initiatives, enforcement priorities and their strategic implications. Reach out to us to set up an initial consultation. The episode closes, as always, with the reminder that Health IT is a dish best served hot.Prefer video? Catch episodes on the POCP YouTube channel

Readings: Exodus 24:12-18 | 2 Peter 1:16-21 | Matthew 17:1-9 | Psalm 2. Preached for the Last Sunday after the Epiphany (2026-02-15).

Dirk Baker has written a book about Kid Gleason.  Most famous for his time as the manager of the 1919 Chicago White Sox who threw the World Series, Gleason had an illustrious career as a player, coach, and manager in Major League Baseball.  Baker wants to share the whole story of the second-generation Irish American.

Alex Gleason was one of the main architects behind Donald Trump's Truth Social. Now he focuses on the intersection of nostr, ai, and bitcoin. We explore open source ai agents, such as OpenClaw, and the wider implications of the tech on society.Alex on Nostr: https://primal.net/p/nprofile1qqsqgc0uhmxycvm5gwvn944c7yfxnnxm0nyh8tt62zhrvtd3xkj8fhggpt7fyClawstr: https://clawstr.com/Soapbox Tools: https://soapbox.pub/toolsMy bot's nostr account: https://primal.net/p/nprofile1qqsfzaahg24yf7kujwrzje8rwa7xmt359tf9zyyjeczc9dhll30k8pgmlfee2 EPISODE: 190BLOCK: 935786PRICE: 1422 sats per dollar(00:02:30) Value-for-value, no sponsors, and show philosophy(00:02:39) Alex Gleason returns to talk AI(00:03:56) From vibe coding to open-source agents with memory(00:05:24) Messaging-first UX: Signal, Nostr, WhatsApp as AI interfaces(00:06:10) Why chatbots beat traditional AI apps for mainstream users(00:07:07) Open protocols pain vs closed platforms; Bitcoin and Nostr(00:08:52) Automating social games: price tracker and agent posting on Nostr(00:10:01) AI mediators for collective action, constitutions, and nonprofits(00:11:46) Scaling governance: trust, bias, and Discord vs freedom tech(00:13:14) Bot barriers on centralized messengers and need for open chat(00:14:04) Clawstr: decentralized AI-to-AI discussions on Nostr(00:15:21) Hype vs reality in AI agents; emergent behaviors and money(00:16:26) Agentic payments: bots with Cashu wallets and earnings(00:18:40) Agents solving UX pain: relay management, keys, and UTXOs(00:20:00) Cold storage approvals with chat agents: a new wallet paradigm(00:20:22) Specialized agents, skills, and distribution challenges(00:22:34) Cost tradeoffs: pay another agent vs build skills yourself(00:24:55) Token burn lessons(00:27:44) Beyond OpenClaw: bloated stacks, Icarus, and cost-optimized agents(00:28:52) Hybrid model routing: local small models with cloud for heavy lifts(00:29:47) Agents paying humans directly: disintermediating platforms(00:30:47) Voice, screens, and form factors: AirPods, text, and brain chips(00:33:01) Apple, privacy branding, and the Siri gap(00:34:35) Enterprise AI choices: Google, Microsoft, trust, and lock-in(00:36:01) Model personalities: Gemini concerns and OpenAI "openwashing"(00:37:23) Obvious agent UX wins: flights, rides, and social media shifts(00:38:50) Local-first social: group chats, neighbors, and healthier networks(00:40:16) Antiprimal.net: standardizing stats from Primal's caching server(00:43:34) Open specs, documentation via AI, and trust tradeoffs(00:45:18) Indexes vs client-side scans: performance and verification(00:46:20) APIs, rate limits, and a market for paid Nostr data(00:47:57) Agents and DVMs: paying sats for services on demand(00:48:49) Degenerate bots: LN Markets, costs, and Polymarket curiosity(00:50:42) Truth feeds for agents: Nostr, webs of trust, and OSINT sources(00:53:51) Post-truth reality: verification, signatures, and subjectivity(00:56:04) Polymarket mechanics: on-chain prediction markets and signals(01:00:10) Trading perception vs truth; sports markets as timelines(01:01:45) The Clawstr token saga: hype, claims, and misinformation(01:07:11) Why meme coins are scams: no equity, utility myths, slow rugs(01:08:55) Pulling the rug back: swapping out, fallout, and donations(01:10:49) Aftermath: donating to OpenSats and lessons learned(01:12:14) Prediction markets vs meme coins: societal value distinction(01:15:25) Iterating beyond OpenClaw and MoltBook; experiments on Nostr(01:18:00) Do bots need Clawstr? Segregating AI content and labels(01:21:02) Reverse CAPTCHA: proving bot-ness and the honor system(01:23:38) Souls, prompts, and token costs; agents with personalities(01:27:01) Wrap-up: acceleration, optimism, and next check-in(01:28:21) Open-source models, China's incentives, and local hardware(01:30:06) The dream stack: home server agent, Nostr chat, hybrid modelsmore info on the show: https://citadeldispatch.comlearn more about me: https://odell.xyz

In this episode, Dr. Rena Malik, MD sits down with Dr. Scott Eggener to explore the nuanced landscape of prostate cancer screening, diagnosis, and treatment. Together, they discuss prevention strategies, highlight the evolving role of exercise and supplements, and clarify the latest advances in biopsy and therapy options—all while emphasizing data-driven, individualized patient care. Listeners will gain essential insights on making informed choices about prostate health, screening practices, and the importance of shared decision-making. In this video discussion,  Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00:00 Introduction 00:00:01 Prostate cancer overview 00:05:32 Prostate cancer prevention 00:09:29 Supplements and vitamins 00:15:24 Medications and prostate cancer risk 00:25:35 Prostate cancer screening guidelines 00:37:55 PSA, markers, MRI, biopsy 00:44:53 Gleason 6 cancer management 00:58:29 Surgery vs. radiation comparison 01:10:49 Side effects of treatment 01:35:45 Testicular and kidney cancer Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

Readings: Micah 6:1-8 | 1 Corinthians 1:18-31 | Matthew 5:1-12 | Psalm 15. Preached for the Fourth Sunday after the Epiphany (2026-02-01).

Ron Gleason talks putting Terry Boers with Dan Bernstein & Dan McNeil full 572 Wed, 28 Jan 2026 00:56:36 +0000 6hk4hOgvI3woUOFsDOZByHbzkJpDYs13 sports Spiegel & Holmes Show sports Ron Gleason talks putting Terry Boers with Dan Bernstein & Dan McNeil Matt Spiegel and Laurence Holmes bring you Chicago sports talk with great opinions, guests and fun. Join Spiegel and Holmes as they discuss the Bears, Blackhawks, Bulls, Cubs and White Sox and delve into the biggest sports storylines of the day. Recurring guests include Bears cornerback Jaylon Johnson, former Bears coach Dave Wannstedt, former Bears center Olin Kreutz, Cubs manager Craig Counsell, Cubs second baseman Nico Hoerner and MLB Network personality Jon Morosi. Catch the show live Monday through Friday (2 p.m. - 6 p.m. CT) on 670 The Score, the exclusive audio home of the Cubs and the Bulls, or on the Audacy app. © 2025 Audacy, Inc. Sports False https://player.amperwav

Jonathan Gleason spent ten years writing the ten essays in his debut collection, Field Guide to Falling Ill (Yale UP, 2026). In them, Gleason braids together strands from a variety of sources – from his experience with a potentially-lethal blood clot, to his imprisoned uncle, to his journey to access medication to prevent HIV – to analyze America's healthcare system and the humiliating, confusing, and depersonalizing effects it can often have. The essays approach medicine from a variety of viewpoints, from Jonathan's perspective as a gay man analyzing the development of HIV medications like AZT and Truvada, to his experience as a Spanish language medical interpreter at a free clinic in Iowa City. But each essay also reminds readers of the importance of understanding the history of our healthcare institutions, and the necessity of feeling less alone when confronted by their myriad failures. Lyrical, poignant, and deeply human, Field Guide to Falling Ill is a poetic approach to understanding medicine in America. For more information on Jonathan and his writing, visit: Jonathan's website: here Jonathan's Substack, Histories of Present Illness: here Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America (Basic Books, 2017). Her new book, Addiction, Inc.: Medication-Assisted Treatment and America's Forgotten War on Drugs, will be released in April 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Jonathan Gleason joins us to talk about his debut essay collection Field Guide to Falling Ill. Drawing from personal experience, history, and medical science, Gleason's moving book explores “the human lives behind the corporate, legal, and cultural practices that shape disease.” During our conversation, we discuss what inspired this book and the techniques Gleason used to create it. He reads from the essays “Inheritance,” about the origins of Taye-Sachs disease, and “Blood in the Water,” which illuminates the life of Gaëtan Dugas, a gay flight attendant who became known as “patient zero” in the beginning of the AIDS epidemic.Gleason is the winner of the inaugural Yale Nonfiction Book Prize and was described by contest judge Meghan O'Rourke as a "layered, reflective, and unusually poised debut." He was a recipient of a 2023 Elizabeth George Grant and a finalist for our very own 2024 Granum Foundation Prize. His work has appeared in the Best American Essays, The Sun Magazine, New England Review, and Kenyon Review. He teaches creative writing at the University of Chicago.Host: Davin MalasarnThe Artist's Statement is brought to you by ⁠The Granum Foundation⁠.

Jonathan Gleason spent ten years writing the ten essays in his debut collection, Field Guide to Falling Ill (Yale UP, 2026). In them, Gleason braids together strands from a variety of sources – from his experience with a potentially-lethal blood clot, to his imprisoned uncle, to his journey to access medication to prevent HIV – to analyze America's healthcare system and the humiliating, confusing, and depersonalizing effects it can often have. The essays approach medicine from a variety of viewpoints, from Jonathan's perspective as a gay man analyzing the development of HIV medications like AZT and Truvada, to his experience as a Spanish language medical interpreter at a free clinic in Iowa City. But each essay also reminds readers of the importance of understanding the history of our healthcare institutions, and the necessity of feeling less alone when confronted by their myriad failures. Lyrical, poignant, and deeply human, Field Guide to Falling Ill is a poetic approach to understanding medicine in America. For more information on Jonathan and his writing, visit: Jonathan's website: here Jonathan's Substack, Histories of Present Illness: here Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America (Basic Books, 2017). Her new book, Addiction, Inc.: Medication-Assisted Treatment and America's Forgotten War on Drugs, will be released in April 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Jonathan Gleason spent ten years writing the ten essays in his debut collection, Field Guide to Falling Ill (Yale UP, 2026). In them, Gleason braids together strands from a variety of sources – from his experience with a potentially-lethal blood clot, to his imprisoned uncle, to his journey to access medication to prevent HIV – to analyze America's healthcare system and the humiliating, confusing, and depersonalizing effects it can often have. The essays approach medicine from a variety of viewpoints, from Jonathan's perspective as a gay man analyzing the development of HIV medications like AZT and Truvada, to his experience as a Spanish language medical interpreter at a free clinic in Iowa City. But each essay also reminds readers of the importance of understanding the history of our healthcare institutions, and the necessity of feeling less alone when confronted by their myriad failures. Lyrical, poignant, and deeply human, Field Guide to Falling Ill is a poetic approach to understanding medicine in America. For more information on Jonathan and his writing, visit: Jonathan's website: here Jonathan's Substack, Histories of Present Illness: here Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America (Basic Books, 2017). Her new book, Addiction, Inc.: Medication-Assisted Treatment and America's Forgotten War on Drugs, will be released in April 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/drugs-addiction-and-recovery

Jonathan Gleason spent ten years writing the ten essays in his debut collection, Field Guide to Falling Ill (Yale UP, 2026). In them, Gleason braids together strands from a variety of sources – from his experience with a potentially-lethal blood clot, to his imprisoned uncle, to his journey to access medication to prevent HIV – to analyze America's healthcare system and the humiliating, confusing, and depersonalizing effects it can often have. The essays approach medicine from a variety of viewpoints, from Jonathan's perspective as a gay man analyzing the development of HIV medications like AZT and Truvada, to his experience as a Spanish language medical interpreter at a free clinic in Iowa City. But each essay also reminds readers of the importance of understanding the history of our healthcare institutions, and the necessity of feeling less alone when confronted by their myriad failures. Lyrical, poignant, and deeply human, Field Guide to Falling Ill is a poetic approach to understanding medicine in America. For more information on Jonathan and his writing, visit: Jonathan's website: here Jonathan's Substack, Histories of Present Illness: here Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America (Basic Books, 2017). Her new book, Addiction, Inc.: Medication-Assisted Treatment and America's Forgotten War on Drugs, will be released in April 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jonathan Gleason spent ten years writing the ten essays in his debut collection, Field Guide to Falling Ill (Yale UP, 2026). In them, Gleason braids together strands from a variety of sources – from his experience with a potentially-lethal blood clot, to his imprisoned uncle, to his journey to access medication to prevent HIV – to analyze America's healthcare system and the humiliating, confusing, and depersonalizing effects it can often have. The essays approach medicine from a variety of viewpoints, from Jonathan's perspective as a gay man analyzing the development of HIV medications like AZT and Truvada, to his experience as a Spanish language medical interpreter at a free clinic in Iowa City. But each essay also reminds readers of the importance of understanding the history of our healthcare institutions, and the necessity of feeling less alone when confronted by their myriad failures. Lyrical, poignant, and deeply human, Field Guide to Falling Ill is a poetic approach to understanding medicine in America. For more information on Jonathan and his writing, visit: Jonathan's website: here Jonathan's Substack, Histories of Present Illness: here Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America (Basic Books, 2017). Her new book, Addiction, Inc.: Medication-Assisted Treatment and America's Forgotten War on Drugs, will be released in April 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/book-of-the-day

GraceLife Fam.. Thank you for listening us today!

Readings: Isaiah 49:1-7 | 1 Corinthians 1:1-9 | John 1:29-42 | Psalm 40:1-12. Preached for the Second Sunday after the Epiphany (2026-01-18).

The first images of a "protector" that flash through our minds might be the warrior, the superhero, the movie star physically holding back evil from invading the world…. Our lower school head, Colin Gleason, casts a different vision: the benevolent king, the merciful brother, the knight at vigil in the sanctuary. Yes, our role as fathers is to protect—most often through a steady presence that communicates security to our children. When we do our job well, they can live with confidence. In his talk from the Fatherhood Conference last fall, Colin identified five battlegrounds for establishing this kind of security, most of which are in our own homes. Also on the Forum: The Father as a Guide to the World featuring Michael Moynihan The Father as Presence featuring Andrew Reed Featured Opportunities: The Art of Teaching Boys Conference at The Heights School (May 6-8, 2026)

Interview withStefan Gleason, CEO of Money Metals ExchangeNick Smart, Director & CEO of ValOre MetalsRecording date: 7th January 2026Platinum group elements have emerged from years of undervaluation into what industry executives describe as a fundamental supply-demand inflection point. The second half of 2025 witnessed platinum prices nearly double, driven by structural changes across industrial, jewelry, and investment demand against severely constrained supply. For investors seeking precious metals exposure with distinct fundamentals from gold, the platinum story presents a compelling case rooted in geological scarcity, industrial necessity, and market imbalances forecast to persist through 2030.The supply challenge stems from extreme geological concentration combined with economic realities. While platinum occurs in earth's crust at similar abundance to gold—a few parts per billion—concentrated economic deposits are far scarcer. Global primary platinum production totals just 6 million ounces annually versus 120-130 million ounces for gold. More critically, 90% of platinum reserves sit within South Africa's Bushveld Complex, where aging deep-level underground mines face rising costs and operational difficulties. Outside South Africa, platinum production occurs primarily as a mining byproduct, meaning supply cannot respond to price signals. As Stefan Gleason, CEO of Money Metals Exchange notes, even prices ten times higher won't trigger meaningful supply responses given massive underinvestment and geopolitical constraints.Demand dynamics have shifted dramatically across three sectors. Industrial demand is strengthening contrary to earlier electric vehicle projections, with 75% of new US vehicles remaining internal combustion engines while hybrids—which consume more platinum and palladium than conventional engines—represent the fastest-growing automotive segment globally. Major manufacturers like Ford and Volkswagen are shifting production lines toward hybrids due to superior profit margins and customer acceptance. Nick Smart, CEO of ValOre Metals and a 21-year Anglo American veteran, emphasizes this durability stems from infrastructure limitations and automotive economics.The jewelry sector presents another growth vector as gold reaches twice platinum's price—a relationship inverted only in the past decade. Manufacturers and consumers in India and China are shifting to platinum for cost relief while maintaining luxury appeal, with platinum offering white gold substitution at less than half gold's cost. Investment demand, while currently small at roughly 1% of precious metals sales, is maturing rapidly. China has opened platinum hedging markets, creating what Gleason describes as "a three-way pull" between London shortages, US inventory builds, and new Chinese infrastructure.Physical market stress signals are acute. Above-ground inventories have fallen below six months of supply—what Gleason characterizes as "totally unsustainable." London financing shortages have driven lease rates to 12-15% annualized, creating cascading effects across refineries, users, and producers. The entire above-ground platinum supply could be absorbed with just $6 billion in capital.Looking forward, market forecasts project persistent deficits of approximately 700,000 ounces annually through 2030 against total production of 6 million ounces, even accounting for all known development projects. Ivanhoe's Platreef Mine represents the only recently commissioned PGE project, taking decades to reach its 300,000-ounce phase one capacity. Smart acknowledges the difficulty: "It's very difficult to see how that deficit gets bridged."For investors, the investment thesis centers on structural supply-demand arithmetic rather than speculative narratives. The combination of geological concentration, years of underinvestment, resilient automotive demand, jewelry substitution, and emerging investment infrastructure creates conditions for sustained revaluation. Recommended allocation strategies include 1-2% of precious metals holdings through physical platinum for long-term holding or mining equities focused on projects outside South Africa for geographical diversification.Learn more: https://cruxinvestor.comSign up for Crux Investor: https://cruxinvestor.com

In this explosive and deeply personal episode of the 3-time award-winning Devon & The Duke podcast, WWE Hall of Famer Devon Dudley and Duke Loves Rasslin pull back the curtain on the reality of life in the wrestling business. From heartwarming family bonds to firing back at internet rumors, this is Devon like you've never heard him before.What's Inside This Episode:The Bliss-Cabrera Connection: Devon opens up about his genuine, close-knit friendship with Alexa Bliss and her husband, musician Ryan Cabrera. Hear the stories of their bond outside the ring and why they are considered family.Calling Out the Dirtsheets: Devon doesn't hold back as he addresses the "keyboard warriors" and gossip sites. He sets the record straight regarding disrespectful accusations about his relationships with female peers, emphasizing the importance of family values and professional respect.A Blast from the Past with Big Vito: Laughter ensues as Devon recounts a surprise visit from Big Vito to his wrestling school. The duo reminisces about their "rookie" days in the early 90s, training under the legendary WWE Hall of Famer Johnny Rodz.Respecting the Craft: A look at what it takes to transition from the "Gleason's Gym" era to running a modern-day wrestling academy.And Much More: Insights into the current state of the industry, locker room etiquette, and the usual unfiltered banter you can only get from Devon and Duke!Why You Can't Miss This:Whether you're a die-hard ECW original fan or a follower of the modern WWE landscape, this episode bridges the gap between eras. Devon Dudley proves that while he may be "testifying," his priority has always been his family, his integrity, and the brothers and sisters he's made along the way.Stop listening to the rumors and hear the truth from the man who lived it.#WWE #DevonDudley #AlexaBliss #RyanCabrera #ProWrestling #DukeLovesRasslin #TheDudleyBoyz #WrestlingPodcast #JohnnyRodz #BigVito #WrestlingNews #HallOfFame** Shop better hydration today. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LiquidIV.Com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ & use the promo code DukeLovesRasslin to save on your next order! ****All views expressed are that of those expressing them. Pull Up Your Skinny Jeans if you don't like it! **

This week’s episode brings back writer and musician Brett Gleason, and I was so happy to reconnect with him! We talked about a couple of big shifts he has made recently: leaving New York for LA after twenty years, and his move from music to writing. It was cool to realize we had both made similar changes in our late thirties, though that was nearly twenty years ago for me! Brett and I also discussed one of his songs, “Sensory Deprived,” why he values the process of writing, and so much more. I’m always so excited to have the chance to talk with Brett, and I know you’ll love this episode, too. Brett Gleason is the author of the confessional memoir in progress, ‘Moody & Gay' – focusing on his experiences as a bipolar, gay musician from New York. A creative writing graduate of the New School in NYC, he moved to Los Angeles after a career as a performer and recording artist and is now once again writing while working in the music industry as a marketing professional.  Brett writes to make the unseen seen, to find the truth behind the story, even when he was at fault. This creates writing that is often intimate and vulnerable, literary but straightforward. His works in progress can be found on his Substack where he shares short accounts, constantly updated as he develops his voice and digs deeper into his past. Connect with Brett:WebsiteSubstackInstagramTikTokFacebook This podcast is powered by my subscribers on Patreon who, in addition to the warm feeling they get from co-creating with me, get lots of sweet perks including bonus podcast episodes, free downloads, zines, and more! This week's bonus podcast will feature an extended conversation with today's guest, Brett where we get a little saucy!  Learn more right here!

Host Dr. Jay Anders welcomes back Amy Gleason, Acting Administrator of the U.S. DOGE Service and Strategic Advisor to the Centers for Medicare & Medicaid Services (CMS). Together they discuss healthcare data interoperability challenges and CMS's initiatives, including efforts to modernize systems and combat Medicare fraud through enhanced data access and AI implementation. This is a must-listen for anyone in health tech. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Readings: Jeremiah 31:7-14 | Ephesians 1:3-6,15-19a | Matthew 2:1-12 | Psalm 84:1-8. Preached for the Second Sunday after Christmas (2026-01-04).

Sundance feature programmer Ania Trzebiatowska joins the show to talk about curation as craft, responsibility, and intuition. From her roots in Poland to running Krakow's Off Camera festival, working in acquisitions at Visit Films, and programming U.S. and world documentary features at Sundance, Ania reflects on how taste is formed and why being pleasantly surprised when viewing submissions still matters most.We discuss the realities filmmakers obsess over, including who you know, timing, marketplace “success,” and why Vimeo analytics do not tell the full story. Ania breaks down what actually happens behind the scenes at Sundance, how programmers balance limited slots with thousands of film submissions, and why being the right fit matters more than trends or agendas.She shares why festivals need balance between urgent, heavy films and work that is entertaining, humane, and emotionally alive. Drawing from examples like André Is an Idiot and Gleason, Ania explains how character-driven storytelling can carry even the most difficult subjects. Advice to filmmakers: do your research, be clear about what you are making, and remember that programmers are rooting for you, even when the answer might still be no.What Movies Are You Watching? Listen to all episodes on Spotify, Apple Podcasts, and more, as well as at www.pastpresentfeature.com. Like, subscribe, and follow us on our socials @pastpresentfeature The Past Present Feature Film Festival - Nov. 20-22, 2026 in Hollywood, CA - Submit at filmfreeway.com/PastPresentFeature

A diagnosis should bring clarity, not confusion or fear. Yet for decades, men have been handed a Gleason score and told it defines their future. In this episode, Dr. Stephen Petteruti challenges the long-standing reliance on Gleason scores and explains why they fail to measure what matters most: cancer behavior over time. He breaks down how the score originated as a visual estimate and why interpretations vary widely between pathologists.Dr. Stephen explains the difference between static labels and dynamic assessment, showing why sequential PSA trends and modern prostate MRI offer more meaningful insight than a single biopsy result. He also addresses the real risks of biopsy itself, including disruption of tissue, while drawing parallels to outdated medical practices.Question assumptions and take part in a new way of thinking that prioritizes outcomes. Watch the full episode of Why The Gleason Scores Fail Men.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Readings: Isaiah 9:2-7 | Titus 2:11-14 | Luke 2:8-20 | Psalm 96. Preached for Christmas Eve (2025-12-24).

Want to connect with Tj & Plaideau? Send us a text message.A con can be more than a weekend hang—it can be the spark for a local film movement. We sit down with actor Jim Gleason to gear up for CajunCon, swap Wonka and mall-theater memories, and dig into how fandom, policy, and smart planning can power Louisiana's next chapter. Jim's prepping his first con table the intentional way, building a collage of roles across Star Trek Continues, Mayfair Witches, Disney's Secrets of Sulphur Springs, and a long-running audio drama, then pairing it with a simple goal: make every visitor feel like the moment matters. With a rare reunion of three of the original Wonka kids and a custom set build, the event taps pure nostalgia while opening space for real conversations with fans.Voiced by Brian Plaideau Have you been injured? New Orleans based actor, Jana McCaffery, has been practicing law in Louisiana since 1999, specializing in personal injury since 2008. She takes helping others very seriously. If you have been injured, Jana is offering a free consultation AND a reduced fee for fellow members of the Lousiana film industry, and she will handle your case from start to finish. She can be reached at janamccaffery@gmail.com or 504-837-1234. Tell Her NOLA Film Scene sent youSupport the showFollow us on IG @nolafilmscene, @kodaksbykojack, and @tjsebastianofficial. Check out our 48 Hour Film Project short film Waiting for Gateaux: https://www.youtube.com/watch?v=z5pFvn4cd1U . & check out our website: nolafilmscene.com

What if thousands of men are losing their sexual function treating a cancer that was never going to kill them? In this episode, I sit down with Dr. Shawn Zimberg — board-certified radiation oncologist and medical director at Advanced Radiation Centers of New York — to unpack the truth about prostate cancer screening, overtreatment, and what every man over 40 needs to know. Dr. Zimberg reveals that the prostate cancer industry has an overtreatment problem — and genomic testing is exposing which tumors need aggressive treatment and which don't. We break down why PSA is broken, why Gleason scores don't tell the full story, and how cadaver studies show men from their 20s to 80s harbor prostate cancer cells that never become clinically significant. We also dive into the science behind radiation therapy, the BioProtect balloon spacer (Dr. Zimberg has performed nearly 2,000 — more than anyone in the world), and the cutting-edge radioligand therapy changing outcomes for stage 4 prostate cancer. If you're a man, love a man, or work with men in health or performance, this is essential listening. About the guest:Dr. Shawn Zimberg is a board-certified radiation oncologist, medical director at Advanced Radiation Centers of New York, and director of radiation oncology at Bronx Care Hospital. He trained at Memorial Sloan Kettering and has pioneered the use of rectal spacer technology in prostate cancer treatment, having performed nearly 2,000 PioProtect balloon procedures — more than any other physician in the world. *** Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: https://go.neuroathletics.com.au/brain-code-yt Subscribe to The Neuro Experience for more conversations at the intersection of brain science and performance. I'm committed to bringing you evidence-based insights that you can apply to your own health journey. *** A huge thank you to my sponsors for supporting this episode. Check them out and enjoy exclusive discounts: Troscriptions — Get 10% off your first order at https://troscriptions.com/neuro or enter code NEURO at checkout. *** I'm Louisa Nicola — clinical neurophysiologist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ *** Topics discussed:00:00:00 Introduction: The Prostate Cancer Overtreatment Crisis 00:02:11 Understanding the Prostate: Anatomy and Function 00:04:43 The Cancer Paradox: Size Does Not Equal Risk 00:07:43 Radiation Oncology: The Specialty Explained 00:11:08 Lifetime Risk and Genetic Factors 00:15:32 PSA Testing: The Gold Standard Screening Tool 00:20:36 The Diagnostic Journey: MRI and Biopsy Techniques 00:25:27 The Ejaculation Study: Myth or Reality? 00:33:15 Gleason Scores Decoded: Understanding Aggressiveness 00:37:03 Molecular Profiling: Looking Under the Hood 00:39:27 Treatment Pathways: Surveillance, Surgery, or Radiation 00:41:02 Active Surveillance: When Watching is Appropriate 00:43:31 Stage 4 and Radio Ligand Therapy: The New Frontier 00:48:21 Testosterone and Prostate Cancer: The Complex Relationship 00:52:38 Radiation Therapy Explained: DNA Damage and Healing 00:55:28 The Bioprotect Balloon: Revolutionary Rectal Protection 00:56:07 The Therapeutic Ratio: Maximizing Cure, Minimizing Damage 00:46:39 Robotic Prostatectomy and Surgical Options 01:06:36 Prevention and Early Detection: What Men Need to Know 01:08:28 Closing Thoughts and Where to Find Dr. Zimberg Learn more about your ad choices. Visit megaphone.fm/adchoices

Readings: Isaiah 35:1-10 | James 5:7-10 | Matthew 11:2-11 | Psalm 146:4-9. Preached for the Third Sunday of Advent (2025-12-14).

Hosts Mike Guidone and Chris Caputo speak with special guest Mark Gottfried about his time as a Major D1 College Basketball Coach and his current role promoting leadership. Later, former Siena Lacrosse player Ryan McCarthy joins the show to discuss the tragic loss of their coach, Liam Gleason, this week at the age of 41. Finally, the guy's chat with Stony Brook University Men's Basketball Coach Geno Ford about their upcoming season and his path to coaching at the Long Island D1 school.

Readings: Isaiah 11:1-10 | Romans 15:4-13 | Matthew 3:1-12 | Psalm 72:1-7, 18-19. Preached for the Second Sunday of Advent (2025-12-07).

The sudden loss of Siena Lacrosse head coach Liam Gleason has left his Saints and UAlbany communities heartbroken, while the overall lacrosse world is mourning the 41-year old's passing this week. The second-to-last College Football Playoff rankings are out. Alabama, Notre Dame and Miami are in precarious positions with the Crimson Tide the only of those programs playing on conference championship weekend. Plus, Professional Bull Riding's Velocity Tour defending champion Grayson Cole joins the show ahead of PBR's stop at MVP Arena in Albany. And, two of the stars from NBC's comedy "Stumble" join the show!

Big Cinco Sonny Gray Red Sox Steelers Drama RIP Liam Gleason

Brent Gleeson is a Navy SEAL combat veteran, award-winning entrepreneur, author, and acclaimed speaker on topics ranging from leadership and building high performance teams to culture, resilience, and organizational transformation. Upon leaving SEAL Team 5, Brent turned his discipline and battlefield lessons to the world of business and has become an accomplished entrepreneur, best-selling author and acclaimed speaker on topics ranging from leadership and building high performance teams to culture and organizational transformation.  Today on the show we discuss: why Navy SEAL training was easier than overcoming addiction, how fear and anxiety quietly sabotage decision-making and confidence, why motivation fails and discipline wins in the long run, the mindset shift that turns pressure and discomfort into fuel, how identity matters more than goals when rebuilding your life, why eliminating alcohol became the turning point for clarity and leadership and much more. ⚠ WELLNESS DISCLAIMER ⚠ Please be advised; the topics related to mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed. The Adversity Advantage podcast does not endorse or support the claims or opinions of any guests and strongly encourages all viewers and listeners to do their own due diligence before buying products or supporting brands discussed by guests on the show.  If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org.  SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized" by Góes et al. published on September 10, 2025. TRANSCRIPT Natalie DelRocco: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Natalie DelRocco, and today we will be discussing the editorial "Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized." This editorial by Góes, Li, and Chehrazi-Raffle, and Janopaul-Naylor et al. describes genomic risk classifiers, or GRCs, for patients with localized prostate cancer. Like any risk prediction model, GRCs are intended to help identify groups of patients that may benefit from less intense or more intense anticancer therapy. Risk prediction tools can be difficult to bring into clinical practice; they require a lot of validation. And as the authors describe, GRCs in localized prostate cancer are no exception. The authors of this editorial contextualize an article by Janopaul-Naylor et al., which attempts to retrospectively explore the clinical use of three available GRCs for localized prostate cancer: Decipher, Oncotype DX, and Prolaris. Each of these three GRCs is being used in clinical practice currently. In the original article, all three GRCs were associated with less intense therapy being prescribed in practice. However, the editorial authors note that this is likely selection bias due to the observational nature of the study design. It is conceivable that GRCs were more likely ordered to make decisions for patients who were already thought to be good candidates for less intensive therapy. Another weakness of the retrospective study design is that patient level covariates known to be associated with clinical prognosis in localized prostate cancer, such as staging, Gleason score, prostate specific antigen, were unavailable. The authors note that sampling bias may also be an issue. Uninsured patients are not included in the original article, and therefore may impede the ability to make conclusions about the association of GRC use with income level. The editorial authors highlight important study findings as well as these limitations, such as the heterogeneity of interventions following GRC result return. The Prolaris GRC was found to be associated with more surgical interventions, while the Decipher GRC was associated with more androgen deprivation therapy plus radiation. Additionally, patients with active surveillance were more likely to have a GRC in general ordered. While these conclusions are very interesting, the editorial authors note that further exploration and validation, given the retrospective study design and limitations outlined, are needed to fully understand the impact of GRCs in the practice of treating localized prostate cancer. Thank you for listening to JCO Precision Oncology Article Insights. Don't forget to give us a rating or a review and be sure to subscribe so that you never miss an episode. You can find all ASCO shows atasco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Please, thank you, after you… Do manners matter? Are they artifice or virtue? In this rebroadcast from 2019, lower school head Colin Gleason shares how manners can be the building blocks to a richer moral life—the habituation of virtue. He then offers practical advice for families and schools to help even young boys strengthen their "moral muscle" through manners that matter. Chapters: 1:34 Why start in the lower school 3:12 Manners: artifice or virtue? 5:34 Orienting them towards the needs of others 10:06 Manners that matter 13:31 Social manners for small children 17:57 Intergenerational social experiences 21:30 Coaching in advance 27:23 Our example Also on the Forum: Manners: The Art of Happiness by Robert Greving Manners Make (More Than) the Man, review of A Gentleman in Moscow by Robert Greving Featured Opportunities: Mustard Seed Communities, donations for Jamaica hurricane relief The Art of Teaching Boys Conference at The Heights School (January 7-9, 2026 / May 6-8, 2026)

Live dockside on the Banana River is Efram Banana, Scion of the settler Banananinne family, talking about what a lucrative business slavery was even though he disapproves, while Dickman and subcommander Gleason butcher the whole thing up. Sign up for a Backstage Pass and enjoy Hours of exclusive content, Phil's new podcast, Classic podcasts, Bobbie Dooley's podcasts, special live streaming events and shows, and oh so very much more…See omnystudio.com/listener for privacy information.

Readings: Malachi 4:1-2a | Psalm 98 | 2 Thessalonians 3:6-13 | Luke 21:5-19. Preached for the 23rd Sunday after Pentecost (2025-11-16).

Do you have young athletes? Work with young athletes? Or just want to learn more about what young athletes are up against these days when it comes to their training, recovery and mindset? If so, you're going to love today's episode with Dave Gleason! Dave has been coaching young athletes for over 3 decades and […] The post Dave Gleason on a Holistic and Well-Rounded Approach to Young Athlete Development appeared first on Robertson Training Systems.

Send a question for the boys to answer on the next podcast!The matchup we've been waiting for! Gleason vs. Finn! Rocketman Dan, Bags, and Kyle W have all the pregame info you need before our Rockets travel down to take on the Redhawks! Also tune in for the postgame recap of the beat down of NIU and updates for volleyball and both basketball teams...TOL!!

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

On this weeks episode of One For The Road I am joined by Brad Garrett is an Emmy and SAG Award winning actor, comedian, and writer. He won three Emmys for his role as "Robert Barone" on the iconic television series EVERYBODY LOVES RAYMOND and received an Emmy nomination along with a Screen Actors Guild nomination for Outstanding Lead Actor in a Miniseries or Movie for his portrayal of "The Great One" in the telefilm GLEASON. Brad most recently co-starred in the Apple TV Plus series HIGH DESERT, and guest starred in the Peacock series BUPKIS following Pete Davidson's life. He starred in FX's FARGO (Season 2) as well as the Jim Carrey-produced Showtime series I'M DYING UP HERE (Season 2). He is also Co-creator/Executive Producer with David E. Kelley on BIG SHOT (Disney+). In features, Brad appears in CHA CHA REAL SMOOTH (Apple) directed by Cooper Raiff and starring Dakota Johnson as well as WILDFLOWER with Jean Smart and Dash Mihok, which premiered at Toronto International Film Festival. He also co-starred opposite Julianne Moore in GLORIA BELL (A24) directed by Sebastian Lelio.If you want to connect with me via Instagram, you can find me on the instahandle @Soberdave https://www.instagram.com/soberdave/or via my website https://davidwilsoncoaching.com/Provided below are links for services offering additional help and advice.www.drinkaware.co.uk/advice/alcohol-support-serviceshttps://nacoa.org.uk/Show producer- Daniella Attanasio-MartinezInstagram - @TheDaniellaMartinezhttps://www.instagram.com/thedaniellamartinez/www.instagram.com/grownuphustle Hosted on Acast. See acast.com/privacy for more information.

Pastor Sean Gleason's message “Do Not Covet” teaches that coveting is a heart issue that pulls us away from God's love and fuels jealousy, competition, and selfish ambition. Using the story of the Samaritan woman at the well, he shows how misplaced desire leads to emptiness until we find fulfillment in Jesus, the living water. The cure for coveting is daily encounters with God, humility, and delighting in Him—because when we find satisfaction in His radical love, we need nothing else.

Fifty years after it first terrified — and amused — audiences, “The Giant Spider Invasion” is crawling back onto the screen. The cult classic about extraterrestrial, blood thirty spiders was filmed in the Gleason, Wisconsin area and is beloved by campy horror fans. It even got the Mystery Science Theater 3000 treatment. Now, “The Giant Spider Invasion” is being reimagined for its 50th anniversary, with new scenes filmed in northern Wisconsin and a theater release around Halloween. Dan Davies is a Wisconsin native himself who has been cast as the lead actor in the new footage. He talked with WPR’s Shereen Siewert about the film.

AI has existed for decades, but modern deep learning is finally delivering precision decisions in clinic. Dr. Spratt details how ArteraAI's predictive biomarker—validated on long-term randomized data—can spare roughly two-thirds of eligible men from ADT without compromising outcomes. We unpack ADT's quality-of-life trade-offs, practical training and nutrition strategies to preserve muscle, and where AI is headed next (post-surgery models, higher-risk disease). You'll also hear a clear framework for shared decision-making so men are treated as people, not just numbers.Key Points✅ AI meets prostate cancer. ArteraAI, developed by Dr. Daniel Spratt's team, is now part of the NCCN guidelines—helping doctors know which patients truly benefit from hormone therapy.✅ Two-thirds can skip ADT. Long-term data from the RTOG 9408 trial show most men can avoid the side effects of hormone therapy without affecting outcomes.✅ Quality of life first. Treatments should improve survival or well-being—if they don't, they shouldn't be used.✅ Lifestyle still matters. Exercise, protein, and resistance training help men on ADT preserve muscle and energy.✅ The future is personalized. New AI models will soon guide therapy for higher-risk patients and integrate full-body health data for truly tailored care.⏱️ Time-Stamped Highlights00:00 – Why AI in prostate cancer now? From buzzword to bedside with ArteraAI.01:30 – Deep learning vs. “human-defined” inputs; beyond Gleason to hundreds of slide features.03:10 – Landmark validation: RTOG 9408 and how the model predicts who benefits from ADT.05:00 – ADT trade-offs: longevity vs. libido, energy, bone/muscle; treat only if it improves life or survival.07:15 – “Exercise is medicine”: the 10-minute rule, protein targets, and resistance training on ADT.09:00 – Current indication: primarily intermediate-risk (Gleason 7) men receiving radiation.10:45 – What's next: models for higher-risk and post-prostatectomy patients; shorter-course ADT questions.13:00 – “Black box” & explainability: why robust external validation matters for trust.15:10 – Access & coverage: ordering via online portal; CMS coverage; what patients can ask their doctors.17:20 – Shared decision-making: reduce PSA anxiety; treat the person, not the number.___________________________________

In his message “Do Not Lie” from the Ten Commandments series, Pastor Sean Gleason taught that lying is the ultimate breaker of trust—not only with people, but with God and ourselves. From the serpent's deception in the Garden to the lies of Ananias and Sapphira, Pastor Sean showed how subtle compromises and “white lies” open the door to the enemy, the father of lies. But every time we choose truth—even when it's painful—we lead people closer to Jesus, encounter God's grace, and grow in authenticity. Radical love for God is revealed by always telling the truth.